PROTAC CARM1/IKZF3 degrader-1

PROTAC CARM1/IKZF3 degrader-1 (Compound 074) inhibits CARM1, reduces the methylation level of its substrate BAF155. PROTAC CARM1/IKZF3 degrader-1 is the PROTAC degrader for IKZF 1/3 through a CRBN-dependent pathway. PROTAC CARM1/IKZF3 degrader-1 inhibits the expression of MYC protein, thereby inhibiting the proliferation of a variety of multiple myeloma cells. PROTAC CARM1/IKZF3 degrader-1 induces apoptosis in cell H929. PROTAC CARM1/IKZF3 degrader-1 overcomes immunomodulatory drugs (IMiD, such as pomalidomide) resistance. PROTAC CARM1/IKZF3 degrader-1 can be used in cancer and immunology research[1]. (Pink: ligand for target protein CARM1/IKZF3 ligand 1 (HY-172369) ; Active form of target protein ligand: EZM 2302 (HY-111109) ; Black: linker (HY-21999) ; Blue: ligand for E3 ligase Cereblon Thalidomide 4-fluoride (HY-41547) )

Product Specifications

UNSPSC

12352005

Target

Apoptosis; Histone Methyltransferase; IKZF Family; PROTACs

Related Pathways

Apoptosis; Epigenetics; Immunology/Inflammation; PROTAC

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Smiles

ClC1=C(C2=NC(C3=C(C)ON=C3C)=C(C)C(N4CC5(CCN(C(CCCCCNC6=C(C(N(C7C(NC(CC7)=O)=O)C8=O)=O)C8=CC=C6)=O)CC5)C4)=N2)C=C(OC[C@@H](CNC)O)C=C1

Molecular Formula

C46H54ClN9O8

Molecular Weight

896.43

References & Citations

[1]Ni W, et al. Dual CARM1-and IKZF3-targeting: a novel approach to multiple myeloma therapy Synergy between CARM1 inhibition and IMiDs[J]. Molecular Therapy Oncology, 2025.